B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $13
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
B. Riley Securities analyst William Woods maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $18 to $13.
B. Riley Securities analyst William Woods maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $18 to $13.